March 2026 Research Update

This month's treatment studies add a clearer picture that outcomes in AL amyloidosis depend on both the anti-plasma-cell therapy used and the specific organ situation a person is in, especially when the heart is involved. One prospective trial in newly diagnosed advanced cardiac disease reported substantial blood (light-chain) response rates over longer follow-up, while smaller real-world reports explored newer immune therapies and supportive heart-failure medicines with signals of benefit but also meaningful risks in very sick groups. Together, these studies show active progress in treatment options, but the strongest evidence this month still comes from larger cohorts and a phase 2 trial rather than single-patient reports. [1] [2] [3]

In a phase 2 study of daratumumab plus bortezomib and dexamethasone (Dara-VD) for newly diagnosed Mayo 2004 stage IIIA and IIIB AL amyloidosis, about half of patients reached a complete blood response by 24 months, while heart responses were less common and tended to develop over time. The report also noted that organ responses continued to improve after 12 months, which fits what many patients experience: organ recovery can lag behind the blood response. The study reported 4-year overall survival of 60%, and it did not find a significant survival difference between stage IIIA and IIIB in this small cohort. [1]

A large real-world matched analysis looked at SGLT2 inhibitors (medicines often used for heart failure and diabetes) in people with heart failure related to AL or ATTR amyloidosis. In the AL group, SGLT2 inhibitor use was linked with lower death rates, fewer hospitalizations, and better kidney outcomes over 12 months compared with matched controls. Because this was based on medical records rather than a randomized trial, it cannot prove the medicine caused the differences, but it strengthens interest in SGLT2 inhibitors specifically in amyloid-related heart failure. [2]

Several small reports focused on newer T-cell engaging medicines used in relapsed or hard-to-treat AL amyloidosis, where options can be limited. In a 6-patient series of talquetamab, most patients had deep blood responses (including MRD-negative results when tested), but serious problems were also reported in this heavily pretreated group, including infections and worsening heart failure in some patients. Separately, a 13-person series using BiTE therapies described a strategy of giving siltuximab (an IL-6 blocker) guided by daily CRP tests to prevent cytokine release syndrome, and no CRS events were reported; the two AL patients in that series had suppression of free light chains and no treatment-related toxicity reported. [3] [4]

Two case reports highlighted how quickly a BCMA-directed bispecific antibody (teclistamab) may reduce the harmful light chains in select situations, but these single-patient stories cannot predict what will happen for most people. One patient with advanced AL-related cardiomyopathy had a rapid MRD-negative complete blood response within 2 weeks and was able to proceed to heart transplant during the same hospitalization, with favorable early post-transplant outcomes reported. Another report described a patient with cardiac AL amyloidosis who had a suboptimal response to first-line Dara-CyBorD and was switched early to teclistamab, but detailed outcomes were not provided in the summary. [5] [6]

For patients who undergo autologous stem cell transplant, a large single-center analysis reported high blood and organ response rates after transplant and improving survival across more recent treatment eras. It also reported low treatment-related mortality (2.6%) and identified factors linked with better or worse long-term outcomes, such as achieving at least a very good partial response after transplant. This kind of long follow-up helps place newer treatments in context by showing what outcomes have looked like with intensive therapy in selected patients. [7]

One small comparative study in cardiac amyloidosis patients needing pacemakers suggested that left bundle branch area pacing produced a narrower paced heartbeat pattern and fewer heart-failure worsening events than right ventricular pacing during follow-up, while death rates and overall complications were similar between groups. Most participants had ATTR rather than AL amyloidosis, so it is not specific to AL, and the study was retrospective and non-randomized. It still adds to ongoing efforts to tailor supportive heart care for amyloidosis patients who require devices. [8]

This month adds both reassurance and realism about treatment progress: deeper blood responses are increasingly achievable in studies, but organ recovery, especially in the heart, can be slower and harder to reach. Some findings may matter now in practice settings where these approaches are already used (for example, daratumumab-based regimens and supportive heart-failure medicines), while the newer immune therapies and CRS-prevention strategies are still early and based on small, selected groups. What remains uncertain is how these newer approaches compare head-to-head with standard care and how safe they are across broader AL populations, particularly for people with advanced heart involvement. These studies mainly help clarify which directions are promising and where larger prospective trials are still needed. [1] [2] [3] [4] [5] [6] [7] [8]

This month's prognosis studies make it clearer that measuring organ function carefully can separate people into meaningfully different risk groups, even when they share the same overall diagnosis of amyloidosis. Across large cohorts, heart imaging measures and short-term risk scores helped predict survival in cardiac amyloidosis, while early kidney function change over 1 year strongly signaled longer-term kidney outcomes in renal-dominant AL amyloidosis. The common message is that single numbers often do not capture risk well, and combining clinical measures can sharpen the picture of what may happen next. [9] [10] [11]

In a large French cohort of 2,244 people with cardiac amyloidosis (including 557 with AL), survival differed across common heart-failure patterns based on pumping function. Median survival was shorter in those with more reduced heart pumping function, and the authors built a decision tree combining ejection fraction with additional imaging measures to sort 4-year mortality into four risk groups. This helps explain why two people with "cardiac amyloidosis" can have very different outlooks depending on how the heart muscle is functioning beyond the basic ejection fraction. [9]

Two studies focused specifically on AL cardiac amyloidosis and highlighted different ways imaging might capture severity or change. One prospective study reported that a cardiac MRI-derived measure called myocardial work efficiency below 72.2% was linked to higher mortality, and adding it to Mayo 2004 stage improved risk prediction compared with Mayo stage alone. A smaller retrospective study suggested that improvement in echocardiography strain measures (including GLS and right-sided heart strain) tended to move together and could appear within 1 year, with a trend toward better survival among those classified as responders. [12] [13]

For people with kidney-dominant AL amyloidosis and little extra-kidney involvement, a large retrospective cohort study found generally favorable long-term outcomes, but early kidney function decline stood out as an important warning sign. A drop in eGFR of more than 20 mL/min/1.73 m2 in the first year independently predicted higher mortality and much faster progression to end-stage kidney disease. This supports the idea that the first year after diagnosis and treatment start can reveal whether the kidneys are stabilizing or continuing to worsen. [11]

A multicenter study developed the PACE score to estimate the chance of death within 6 months in newly diagnosed AL amyloidosis patients treated with daratumumab-based frontline regimens. The score used four factors (including NT-proBNP level, age, cytogenetics, and performance status) and separated patients into low, intermediate, and high risk groups with very different early mortality rates. This kind of tool does not determine what will happen to an individual, but it aims to make early risk easier to communicate and study consistently across centers. [10]

These studies mainly add understanding about prognosis rather than introducing new treatments. The clearest near-term impact is that research is moving toward more personalized risk estimates that use combinations of heart imaging, blood markers, and early kidney trends instead of relying on a single test result. What remains uncertain is how best to use newer imaging measures and risk scores across different hospitals and scanners, and whether changing care based on these measures improves outcomes. For patients and caregivers, this month helps clarify why follow-up testing often includes multiple heart and kidney measurements, because each adds a different piece to the risk picture. [9] [12] [13] [11] [10]

This month's diagnosis and biology studies point in two directions at once: improving early detection and reducing misclassification. Several studies evaluated new or overlooked tests that might help identify AL amyloidosis or amyloidosis-related nerve problems, while others showed that lab methods and definitions can change who gets labeled at risk for progression. Together, these studies highlight that accurate diagnosis often depends on combining different types of evidence rather than relying on a single test. [14] [15] [16]

Blood-based markers typically discussed in Alzheimer research were reported to be higher in AL and ATTR amyloidosis, especially when people had polyneuropathy (nerve damage symptoms). In an observational biomarker study, serum p-tau181 was higher in AL and ATTR than in controls, and people with non-amyloid neuropathies did not show this elevation; p-tau217 showed similar changes in one cohort. This raises the possibility that these markers could, after more validation, help distinguish amyloidosis-related neuropathy from other causes and avoid confusion with Alzheimer disease. [14]

Two studies focused on laboratory testing and how the choice of method can change results. A comparative study of free light chain (FLC) tests found that the Sebia ELISA tended to read lower involved light chain levels and missed abnormal kappa/lambda ratios more often than two other assays, especially in lambda disease, and detection improved when combined with serum and urine immunofixation. Separately, a population-based Danish study of revised iStopMM light-chain MGUS criteria reported that 40% of people who met older criteria were reclassified as normal under the revised approach, with no progression to myeloma or AL amyloidosis observed in that reclassified group during follow-up. [15] [16]

One observational study drew attention to an unusual but potentially practical bone marrow smear finding. In 103 AL amyloidosis patients, lilac-colored aggregates on a standard-stained marrow smear were found in 20 patients and confirmed to be amyloid by Congo red staining, and this group more often had kappa-type amyloid and certain organ involvement patterns. In two patients with repeat marrows, these aggregates decreased after therapy, suggesting they may reflect disease burden in at least some cases. [17]

A diagnostic modeling study tested whether serum Raman spectroscopy plus a neural-network classifier could distinguish AL amyloidosis from multiple myeloma using blood samples. The model reported high accuracy with AUCs of 0.94 for AL and 0.96 for myeloma in the studied samples, outperforming several alternative algorithms. This is still an early-stage approach, but it shows active interest in noninvasive tools that might speed up sorting between related plasma cell diseases. [18]

A molecular study examined which cells actually carry the key genetic changes that drive AL amyloidosis and related conditions. Using single-cell and genetic sequencing, driver alterations were found mainly in plasma cells and only rarely in immature B cells, while clonotypic B-cell receptors appeared at very low levels in B-cell compartments. The authors also noted that these rare clonotypic B cells might sometimes lead to false-positive minimal residual disease signals when MRD is tracked by certain sequencing approaches. [19]

Most of these findings matter more for improving diagnostic confidence and research measurement than for changing day-to-day care immediately. The most practical message is that test choice and definitions matter: different free light chain assays can give different numbers, and revised MGUS criteria may reduce over-labeling without missing AL progression in the reported cohort. What remains uncertain is which newer tools (like p-tau blood markers or Raman spectroscopy) will hold up across many hospitals and patient groups, and whether they will be adopted outside research. For patients and caregivers, this month helps clarify why diagnosis often requires multiple complementary tests, and why results should be interpreted in the context of the specific assay and the whole clinical picture. [14] [15] [16] [17] [18] [19]

This month’s case reports show how AL amyloidosis can appear in unexpected ways, and how reaching the correct diagnosis sometimes requires targeted tissue sampling and careful review of clues across organs. The cases also show that disease course can be very different from person to person, ranging from localized disease that stabilizes to rapidly progressive multi-organ disease despite treatment. As single-patient reports, they mainly expand awareness of what is possible rather than predicting what will happen for most people. [20] [21]

Two reports emphasized diagnostic confusion with other conditions. One patient had inflammatory arthritis that was initially labeled as seronegative rheumatoid arthritis, and the final diagnosis of AL amyloidosis secondary to multiple myeloma was reached after muscle and joint imaging plus an ultrasound-guided biopsy. Another patient presented with lower gastrointestinal bleeding and colitis, and a colon biopsy confirmed AL amyloid deposition as part of systemic multi-organ disease. [20] [21]

Several cases highlighted complex overlap with other diseases or exposures. One patient with renal cell carcinoma had both PLA2R-positive membranous nephropathy and AL amyloidosis, and nephrotic syndrome did not improve after nephrectomy but later went into remission after sequential drug therapy. Another report described AL-type cardiac amyloidosis diagnosed in the setting of chronic Brucella infection, with the authors proposing a possible link but not establishing cause and effect. [22] [23]

One case focused on localized airway AL amyloidosis rather than systemic disease. A woman with tracheobronchial AL-lambda amyloidosis had biopsy confirmation with mass spectrometry and no systemic involvement found on the reported workup, and external beam radiotherapy led to disease stabilization and partial symptom improvement. This report adds to the limited real-world information on how localized AL amyloid can be evaluated and managed. [24]

These reports may matter now mainly by helping patients and caregivers recognize that AL amyloidosis can mimic more common problems like arthritis, colitis, or kidney diseases with other causes. They also reinforce that a biopsy (and sometimes specialized typing such as mass spectrometry) is often the key step that turns uncertainty into a clear diagnosis, especially when symptoms are unusual. What remains uncertain is how often these rare presentations occur and which features reliably distinguish them early, because each report describes only 1 person. For most readers, the value is better understanding of the range of presentations and why diagnostic workups can be broad when AL amyloidosis is suspected. [20] [21] [22] [23] [24]